News releases

The Canadian Generic Pharmaceutical Association (CGPA) and Biosimilars Canada continue to work closely with Health Canada, member companies and key stakeholders in the pharmaceutical supply chain to help ensure that Canadian patients continue to have access to high-quality generic and biosimilar medicines.

The Canadian Generic Pharmaceutical Association (CGPA) and Biosimilars Canada continue to work closely with Health Canada, member companies and key stakeholders in the pharmaceutical supply chain to help ensure that Canadian patients continue to have access to high-quality generic and biosimilar medicines. To date, we are not aware of any drug shortages in Canada related to COVID-19.

Biosimilars Canada, a national association representing Canada’s biosimilar medicines industry, today congratulated the Government of Alberta for becoming the second province in Canada to implement a biosimilar “switching” or transitioning program.

Biosimilars Canada, a national association representing Canada’s biosimilar medicines industry, today congratulated the Government of British Columbia for building on the success of its biosimilar switching program and called on other provinces to implement similar programs.

The Advisory Council on the Implementation of National Pharmacare’s Final Report highlights the importance of biosimilar medicines in the sustainable implementation of a national pharmacare program.

Biosimilars Canada, a national association representing Canada’s biosimilar medicines industry, today congratulated the Government of British Columbia for announcing a program in which patients taking originator biologic drugs will be “switched” or transitioned by their clinicians to a biosimilar biologic drug within a six-month period.